ArticleEuropean journal of medical research2025
Revealing sphingolipid metabolism genes as biomarkers for the diagnosis of invasive pituitary adenomas in silico and in vivo.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of biomarkers associated with integrated stress response in pituitary adenomas based on bioinformatics.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study is to reveal key genes related to sphingolipid metabolism for distinguishing the invasive characteristics of pituitary adenomas (PA).
methodsBulk-RNA sequencing datasets related to the invasive pituitary adenomas (IPA) were retrieved from the GEO database and integrated after batch effect correction. IPA-related genes were identified through weighted gene co-expression network analysis (WGCNA) and differential gene expression (DEGs) analysis. Sphingolipid metabolism-related genes were sourced from the GeneCards database and intersected with IPA-related genes to identify IPA-specific metabolism genes (SMGs). Machine learning, including Lasso and SVM-RFE, was used to identify the key genes incorporated into a diagnostic model. The tumor immune microenvironment was analyzed, exploring correlations with key genes. Finally, key genes were validated through immunohistochemistry (IHC) and RT-qPCR in the IPA and PA samples.
resultsFour datasets were included. A total of 228 IPA-related genes were identified, with 10 IPA-SMGs obtained by intersecting with SM-related genes. Machine learning revealed three key genes, SLC27A2, EHD3, and SV2B. A logistic regression model was constructed, and after internal validation with 1000 bootstrap iterations, the ROC curve achieved an AUC of 0.767. Immune infiltration analysis showed that the ratio of endothelial cells and fibroblasts was significantly reduced in the IPA group compared to controls. IHC and RT-qPCR confirmed that SLC27A2 expression was significantly reduced, while EHD3 and SV2B were significantly increased in IPA tissues, which was consistent with the bioinformatics findings.
conclusionThis study identifies key genes potentially involved in the development and progression of IPA, offering new insights into the molecular mechanisms underlying IPA pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.